Literature DB >> 27760871

Rituximab for treating multiple sclerosis: Off-label but on target.

Dennis Bourdette1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27760871     DOI： 10.1212/WNL.0000000000003345

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

1.  The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.

Authors:  László Gulácsi; Valentin Brodszky; Petra Baji; Fanni Rencz; Márta Péntek
Journal:  Adv Ther       Date:  2017-04-10       Impact factor: 3.845

2.  Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study.

Authors:  Martha Rocio Hernández-Preciado; Jazmin Marquez-Pedroza; Nayeli Alejandra Sánchez-Rosales; José de Jesús García-Rivera; Antonio Kobayashi-Gutiérrez; Blanca Miriam Torres-Mendoza; Efraín Chavarría-Avila; Raúl Alejandro Montaño-Serrano; Fernando Cortes-Enriquez; Mario Alberto Mireles-Ramírez
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

3.  The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.

Authors:  Irene Eriksson; Joris Komen; Fredrik Piehl; Rickard E Malmström; Björn Wettermark; Mia von Euler
Journal:  Eur J Clin Pharmacol       Date:  2018-02-10       Impact factor: 2.953

Review 4.  Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies.

Authors:  Jenny J Feng; Daniel Ontaneda
Journal:  Degener Neurol Neuromuscul Dis       Date:  2017-02-01

Review 5.  Health economics of disease-modifying therapy for multiple sclerosis in the United States.

Authors:  Daniel M Hartung
Journal:  Ther Adv Neurol Disord       Date:  2021-02-17       Impact factor: 6.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.